9% normal saline clinical trials

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

This study is looking into a new treatment for people newly diagnosed with type 1 diabetes. It compares a drug called TCD601 (siplizumab) with a dummy treatment (placebo) over 12 months to see if it can help the body keep making its own insulin.